Navigation Links
Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
Date:7/31/2013

quarter of 2013, as compared to the second quarter of 2012.
  • The gross margin on sales of OFIRMEV was 66% for the three and six months ended June 30, 2013, as compared to 48% for the same periods in 2012.
  • "The second quarter saw the continuation of OFIRMEV's strong growth trend, with sales more than doubling year-over-year," said Ted Schroeder, President and CEO of Cadence. "We believe that usage of the product within our broad customer base will continue to increase, and our market share will grow. I'm pleased with the momentum we have been able to maintain with our revenue growth. As a result, we are raising our full year revenue guidance to reflect this trend. We now expect that our net product revenue for 2013 will range between $103.0 million and $105.0 million."

    Financial Results
    Cadence's net product revenue was $24.7 million for the three months ended June 30, 2013, which represents an increase of $13.6 million, or 123%, from the $11.1 million in net product revenue recognized for the three months ended June 30, 2012. For the six months ended June 30, 2013, Cadence reported net product revenue of $48.3 million, an increase of $29.2 million, or 153%, from the $19.1 million reported for the same period in 2012. As of January 1, 2013, Cadence began to recognize revenue at the time that product is sold to a wholesaler, consistent with other companies with products at this stage of commercialization. As a result, the company recorded a one-time adjustment during the six months ended June 2013 to recognize deferred revenue on previously shipped product, resulting in additional net product revenue of $2.6 million and cost of sales of $0.9 million, for a net gross margin impact of $1.7 million during the period.

    For the three months ended June 30, 2013, Cadence reported a net loss of $11.9 million, or $0.14 per share, compared to a net loss of $21.0 million, or $0.25 per share, for the comparable period in 2012. For the six mo
    '/>"/>

    SOURCE Cadence Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Cadence Pharmaceuticals Reports First Quarter 2012 Financial Results
    2. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2012 Financial Results On August 2, 2012
    3. Cadence Pharmaceuticals To Present At The Wedbush PACGROW Life Sciences Management Access Conference In New York City On August 14, 2012
    4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2012 In Boston On September 5, 2012
    5. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
    6. Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results
    7. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
    8. Cadence to Open Finished Medical Device Facility
    9. Cadence Pharmaceuticals to Host Analyst and Investor Day
    10. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
    11. Cadence Pharmaceuticals Estimates Fourth Quarter 2012 Net Product Revenue and Provides Full Year 2013 Revenue Guidance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... YORK , Oct. 30, 2014  The number ... States is growing steadily, thanks to drug ... as a result of the economic downturn, retail clinic ... a year of opportunities, as the number of retail ... researcher,s report, Retail Clinics Market Overview and 2014 ...
    (Date:10/30/2014)... 30, 2014 Molecular Profiles Ltd., a subsidiary ... and Maryland -based Xceleron have announced ... during clinical development that will be launched at AAPS ... This partnership extends Molecular Profiles, new ROADMAP ... earlier this month. The company also has complementary collaborations ...
    (Date:10/30/2014)... Oct. 30, 2014  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced an upcoming ... drug candidate, aldoxorubicin.  The presentation, titled, "Drug Conjugates ... be given by Sant P. Chawla , ... and principal investigator of the Company,s ongoing global, ...
    Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4
    (Date:10/30/2014)... 2014 Global prebiotics market is expected ... a new study by Grand View Research, Inc. Positive ... sugar and fat free products owing to increased concerns ... prebiotics over the forecast period. , View full report ... & beverage was the largest application segment with market ...
    (Date:10/30/2014)... October 30, 2014 The human brain ... more vigorously exercised to help maintain better mental health, ... book ‘Dementia Express: Lose Your Memory in 100 Ways’ ... reasoning and sometimes conflicting attitudes to help keep the ... mind, a reader must decipher the hidden logic within. ...
    (Date:10/30/2014)... Sound Telecom, a leader in the call center industry, ... time they wonder, “Should I use an answering service?” The ... through a series of yes or no questions that ultimately ... are many considerations and scenarios that come into play when ... . This decision infographic serves as a bit of a ...
    (Date:10/30/2014)... Amy Norton HealthDay Reporter ... common plastics, chemical during pregnancy may have effects on genital ... found that baby boys born to moms with greater exposure ... anogenital distance -- the space between the genitals and anus. ... a marker of exposure to androgens ("male" hormones) during pregnancy. ...
    (Date:10/30/2014)... 2014 (HealthDay News) -- Eating a low-carb, high-fat diet ... according to new research. A review of ... diet, that focuses on foods like bacon, eggs, heavy ... seizures in adults whose condition doesn,t improve with medication. ... of people with epilepsy whose seizures are not stopped ...
    Breaking Medicine News(10 mins):Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
    ... Healthcare ( www.siemens.com/healthcare ) ... the Workflow & Solutions Division, Siemens Healthcare, testified before the ... Representatives on the need for healthcare reform. ... ) , , During the hearing, "Comprehensive Health ...
    ... , Supporting individual quality of life and American business ... 24 The U.S. Women,s Chamber of Commerce submitted ... to restore American values and business competitiveness through the ... report include the support of Health Insurance Exchanges, guaranteed ...
    ... Inc. (NYSE: WPI ), a leading specialty ... Inc., has received approval today from the United States ... Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women ... equivalent to Duramed Pharmaceuticals, PLAN B(R), which is indicated ...
    ... memories , WEDNESDAY, June 24 (HealthDay News) -- Researchers ... long-term storage of memories. , Their study showed that ... remember them less well than mice who can perform ... Circuit Genetics at MITs Picower Institute for Learning and ...
    ... shows better survival when compared to those who ... News) -- A new Canadian study adds compelling ... get clot-dissolving treatment for heart attacks should have ... "This study strengthens the guideline recommendations," said Dr. ...
    ... Mich., June 24 Validation and Compliance Institute (VCI), ... FDA regulated industries, will offer a series of Dietary ... (DBA), a division of NSF International. , ... the new GMP regulations for dietary supplements, which the ...
    Cached Medicine News:Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 2Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 3Health News:U.S. Women's Chamber of Commerce Advocates Strong Healthcare Reforms in Support of American Values 2Health News:Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R) 2Health News:Sleep May Be Essential for Long-Term Memory 2Health News:Quick Angioplasty Best After Heart Attacks 2Health News:Quick Angioplasty Best After Heart Attacks 3Health News:Validation & Compliance Institute, LLC, to Provide Dietary Supplement GMP Training for NSF International 2
    BD Vacutainer® Fluoride Tubes - Glass...
    VACUETTE Trace Element tubes - Ridged (safety screw cap) are designed to test trace elements such as Cu, Zn, Pb, etc....
    Inquire...
    VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
    Medicine Products: